Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Current Report on Form 8-K dated October 15, 2025. The filing addresses a corporate update regarding liquidity and capital structure, as well as the resolution of a Nasdaq listing compliance matter.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $133.3 million as of October 15, 2025.
- Capital Structure: 133,002,572 shares of common stock outstanding and pre-funded warrants to purchase up to 73,271,424 shares outstanding as of October 15, 2025.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Debt and Liquidity: No specific debt figures are provided; liquidity is indicated by the cash balance of $133.3 million.
Material Changes and Events
The primary material event reported is the resolution of a Nasdaq listing deficiency. The Company previously received notice on April 30, 2025, that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive trading days. The Company was granted an initial 180-day compliance period ending October 27, 2025.
On October 15, 2025, the Company received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), and the matter is now closed.
Outlook, Risks, and Management Commentary
Management notes that while compliance has been regained, there can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement in the future. No specific financial guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the current trading price of PALI to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the dilution impact of the 73,271,424 pre-funded warrants outstanding.
- Review subsequent filings for any updates on cash burn rate or new financing activities given the $133.3 million cash position.